Genesis Therapeutics recently joined the growing list of AI-powered drug discovery startups receiving venture funding this year. The company closed a $200 million Series B financing round, taking its total funding to date to more than $280 million.
Pharma players, now more than ever, need a new and powerful tool to differentiate their products. We believe the next decade of transformation is digital.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Inertia is a barrier as is the traditional split between the clinical and the data-driven spheres of drug development. While smaller firms have an edge in bridging the gap, big pharma will eventually get there, said panelists at the INVEST conference session.
Notable CEO Matthew De Silva said the company has been able to successfully replicate its automated system, allowing for the export of the company's technology and growth of its commercial use cases.